Compare NICE Ltd (NICE) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NICE Ltd vs Zimmer Biomet Holdings Inc — how do they compare? NICE Ltd trades at $98.12 (market cap $5.94B), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $17.97B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 3× NICE Ltd's market cap, and Zimmer Biomet Holdings Inc pays a 1.02% dividend while NICE Ltd pays none. Which is the better fit depends on your goals.
| NICE | ZBH | |
|---|---|---|
Market Cap | $5.94B | $17.97B |
Sector | Technology | Health |
52-Week High | $153.44 | $104.26 |
52-Week Low | $83.15 | $79.58 |
Enterprise Value | $5.67B | $25.04B |
Dividend Yield | — | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NICE stock trades at $101.47, down 3.82% in the last session, reflecting near-term bearish technical signals. The company maintains strong fundamentals with a P/E of 14.77 and robust profitability, including a 65.12% gross margin and consistent earnings beats in recent quarters. Recent news highlights AI platform deployments with major clients like AOK PLUS and Bluecrest, reinforcing growth in the CX segment. Analyst consensus remains positive with a $118.67 price target, though technical indicators suggest caution amid a bearish overall signal.
The outlook for NICE is supported by solid cloud and AI revenue growth, upward EPS guidance, and a debt-light balance sheet. Key risks include execution challenges in scaling AI offerings and competitive pressures in the customer engagement software market. With no sell ratings from analysts and institutional accumulation, the stock presents a value opportunity for long-term investors despite near-term volatility.
Zimmer Biomet (ZBH) trades at $94.22, down 3.93% on the day, with a bearish technical signal but strong fundamentals including a 69.87% gross margin and three consecutive quarterly earnings beats. Revenue growth is steady, reaching $8.23B in 2025, though net income margin dipped to 8.56%. Recent leadership promotions aim to accelerate commercial transformation, while analyst consensus price target is $104.88, implying 11.3% upside.
The stock presents a value opportunity with a P/E of 22.87 and P/S of 2.17, supported by robust cash flow and dividend payments. Risks include rising debt-to-asset ratio (32.57% in 2025) and competitive pressures. Wall Street sentiment is mixed with 40.48% buy ratings, but technical indicators suggest near-term caution amid bearish moving averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
